Dianthus Therapeutics, Inc. $DNTH Stock Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC decreased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 12.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 65,620 shares of the company’s stock after selling 8,932 shares during the quarter. Dianthus Therapeutics makes up 1.1% of Moody Aldrich Partners LLC’s investment portfolio, making the stock its 26th largest position. Moody Aldrich Partners LLC’s holdings in Dianthus Therapeutics were worth $5,778,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of DNTH. BlackRock Inc. purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth about $401,990,000. Wellington Management Group LLP boosted its position in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after acquiring an additional 634,099 shares during the period. Assenagon Asset Management S.A. boosted its position in Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after acquiring an additional 451,597 shares during the period. Jennison Associates LLC purchased a new position in Dianthus Therapeutics during the 1st quarter valued at about $40,713,000. Finally, Spruce Street Capital LP grew its stake in Dianthus Therapeutics by 25.5% during the 1st quarter. Spruce Street Capital LP now owns 373,274 shares of the company’s stock valued at $31,325,000 after acquiring an additional 75,837 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CAO Edward Carr sold 20,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the transaction, the chief accounting officer owned 20,000 shares in the company, valued at approximately $2,027,600. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anne McGeorge sold 7,750 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the transaction, the director directly owned 1,250 shares in the company, valued at $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 242,429 shares of company stock worth $26,118,913 in the last ninety days. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $82.31 on Thursday. The company has a market capitalization of $4.51 billion, a P/E ratio of -19.83 and a beta of 1.35. The stock’s 50 day moving average price is $93.92 and its 200 day moving average price is $84.17. Dianthus Therapeutics, Inc. has a 52 week low of $32.28 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DNTH. Roth Capital assumed coverage on Dianthus Therapeutics in a report on Tuesday. They issued a “buy” rating and a $113.00 target price on the stock. Truist Financial increased their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target for the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $128.54.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.